The Efficacy of a Soluble Ligand Binding Tumour Necrosis Factor Receptor, Etanercept, in Severe, Steroid Dependant Asthma: a Randomised Controlled Study
Although steroid dependent asthma represents a small population of patients with asthma,
they consume a disproportionately large amount of the health resource burden attributed to
asthma. Treatment options in this group are extremely limited; the development of effective
treatments for this group of patients should be a priority, not only for increasing
individual patient quality of life but for long term reduction of health spending.
This randomised, double blind, placebo controlled, cross over trial will investigate the
efficacy of a soluble TNF receptor, etanercept, in severe, steroid dependant asthma.
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Michael A Berry, MB, ChB
Institute for Lung Health
United Kingdom: Medicines and Healthcare Products Regulatory Agency